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Abstract: Transverse myelitis is a focal inflammatory disorder of the spinal cord which may arise due to different   
etiologies. Transverse myelitis may be idiopathic or related/secondary to other diseases including infections, connective 
tissue disorders and other autoimmune diseases. It may be also associated with optic neuritis (neuromyelitis optica), which 
may precede transverse myelitis. In this manuscript we review the pathophysiology of different types of transverse   
myelitis and neuromyelitis optica and discuss diagnostic criteria for idiopathic transverse myelitis and risk of development 
of multiple sclerosis after an episode of transverse myelitis. We also discuss treatment options including corticosteroids, 
immunosuppressives and monoclonal antibodies, plasma exchange and intravenous immunoglobulins.  
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INTRODUCTION 
  Multiple sclerosis is the prototype of inflammatory disor-
ders affecting the central nervous system. However, there are 
numerous inflammatory conditions, other than multiple scle-
rosis that have the central nervous system as their only or 
preferred target (Table 1). Early recognition of such syn-
dromes is crucial for applying the appropriate therapy that 
can be quite different from that of multiple sclerosis. In this 
review we will focus the discussion on two important disor-
ders closely related to multiple sclerosis: idiopathic trans-
verse myelitis and neuromyelitis optica (Devic’s disease). 
We will briefly discuss the epidemiology and clinical presen-
tations of these diseases and provide detailed discussion on 
the pathophysiology and therapeutic approaches.  
IDIOPATHIC TRANSVERSE MYELITIS  
  Transverse myelitis (TM) is a focal inflammation of   
the spinal cord of different etiologies. It can be idiopathic  
or related/secondary to other diseases. The percentage   
of idiopathic TM is expected to be declining due to the   
advances in neurodiagnostics and the discovery of new   
disease markers.  
Epidemiology and Clinical Profiles  
  The annual incidence of TM in the United States   
is around 4.6 per million per year [1]. The incidence of   
idiopathic TM is about 1.34-4.6 per million per year [2]. 
However, a study by Young and his co-workers found   
much higher numbers (3-5 times higher) in the Australian 
population [2]. TM has a bimodal distribution with two   
distinct peaks: 10-19 and 30-39 years. It shows no racial,   
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familial or gender predilection [1, 3, 4]. About 28% of   
reported cases of TM are in pediatric population [5]. 
  TM typically presents with acute to subacute myelopathy 
[6-12]. The symptoms usually progress over hours to few 
weeks. The thoracic cord is the most common to be affected 
for no clear reasons. Many patients present with flu-like 
symptoms prior to the myelopathy picture. The most   
common symptoms include: back pain (30-50%), lower   
limb paresthesias (80-95%), allodynia (80%), paraparesis 
(50%), bladder symptoms (almost 100%) and sensory   
level (80%).  
  The idiopathic TM proposed diagnostic criteria are 
shown in Table 2 [13]. Abnormal cord signal on spine mag-
netic resonance imaging (MRI) (Fig. 1) can be seen in 
around 75% (50-90%) [11, 14-17]. The cerebrospinal fluid 
(CSF) shows nonspecific signs of inflammation like elevated 
protein level and pleocytosis in about one half of adult pa-
tients, [1, 8, 17, 18] and about 80% of children with TM 
[14]. Oligoclonal bands in CSF are typically absent in non-
MS related TM and if present are usually transient [17, 19]. 
TM is typically monophasic but relapsing TM does occur in 
about 20-30% [20-22]. Male gender, strict white matter in-
volvement and normal CSF parameters seem to increase the 
risk of recurrence [23].  
  The most important findings that increase the chance of 
progression to MS include: abnormal brain MRI, incomplete 
(partial) iTM, the presence of oligoclonal bands in the CSF, 
abnormal visual and somatosensory evoked potentials and 
human leukocyte antigen (HLA) DR-2 status [2, 8, 24-28]. 
The rate of conversion to MS in patients with iTM with brain 
lesions ranges is 44-93% and without brain lesions is 15-
44% [2]. Oligoclonal bands in CSF are frequent with iTM 
(~62% vs. 17%) [2]. 
  Poor prognosticators include: back pain, rapid progres-
sion, cervical spine involvement, spinal shock, denervation 418    Current Neuropharmacology, 2011, Vol. 9, No. 3  Awad and Stüve 
on electromyography (EMG) and the presence of protein 14-
3-3 in the CSF [9, 15, 29-31].  
Pathology, Pathogenesis and Pathophysiology 
  Most of information on TM pathology comes from clini-
copathological cases reports and autopsy studies [32-34]. All 
patients who met the criteria for TM had inflammation. The 
lesions in acute TM are invariably limited to the spinal cord 
with no involvement of other structures in the central nerv-
ous system (CNS). The histopathology is characterized by 
demyelination and axonal loss in addition to gray matter 
involvement. Necrosis and cavitation can result in severe 
Table 1.  Inflammatory Disorders Related to Multiple Sclerosis  
1  Clinically isolated syndromes (optic neuritis, transverse myelitis) 
2  Neuromyelitis optic (Devic’s disease) 
3  Acute disseminated encephalomyelitis (ADEM) 
4  Bickerstaff’s brain stem encephalitis 
5  Neuro-Bahçet’s disease  
6  Neurosarcoidosis 
7  Neuro-Sjogren’s disease  
8  Systemic lupus erythematosus (SLE) 
9  Inflammatory ocular diseases 
10  Central nervous system vasculitis 
11  Arachnoiditis  
12  Paraneoplastic encephalitic syndromes 
13  Steroid-responsive encephalopathy (Hashimoto’s encephalopathy) 
14  Infections ( Inflammatory form of progressive multifocal leukoencephalopathy (PML), neurosyphilis, Whipple’s disease, human T-cell  
lymphoma-leukemia virus (HTLV-1), neuroberreliosis (Lyme’s disease), human immunodeficiency virus (HIV), neurobrucellosis,  
human herpes virus-6 (HHV-6), mycoplasma, subacute sclerosing panencephalitis (SSPE) 
 
Table 2.  Proposed Diagnostic Criteria for Acute Idiopathic Transverse Myelitis  
Inclusion criteria 
·     Development of sensory, motor or autonomic dysfunction attributable to the spinal cord 
·     Bilateral signs and/or symptoms (though not necessarily symmetric)  
·     Clearly-defined sensory level 
·     Exclusion of extra-axial compressive etiology by neuroimaging (magnetic resonance imaging, or myelography; computerized tomography of spine not 
adequate)  
·     Inflammation within the spinal cord demonstrated by cerebrospinal fluid pleocytosis or Elevated IgG index or gadolinium enhancement. If none of the 
inflammatory criteria is met at symptom onset, repeat MRI and LP evaluation between 2-7 days following symptom onset meets criteria 
·     Progression to nadir between 4 hours to 21 days following the onset of symptoms 
(if patient awakens with symptoms, symptoms must become more pronounced from point of awakening)  
Exclusion criteria 
·     History of previous radiation to the spine within the past 10 years 
·     Clear arterial distribution clinical deficit consistent with thrombosis of the anterior spinal artery 
·     Abnormal flow voids on the surface of the spinal cord consistent with arteriovenous malformation 
·     *Serologic or clinical evidence of connective tissue disease (sarcoidosis, Bahçet’s disease, Sjogren’s syndrome, systemic lupus erythematosus,  
mixed connective tissue disorder etc) 
·     *Central nervous system manifestations of syphilis, Lyme disease, human immunodeficiency virus (HIV), human T-cell lymphoma-leukemia  
virus(HTLV-1), mycoplasma, other viral infection (e.g. herpesviridae viruses , enteroviruses) 
·     *Brain magnetic resonance imaging abnormalities suggestive of multiple sclerosis 
·     *History of clinically apparent optic neuritis  
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cases. The cord involvement is usually central, uniform and 
symmetric in comparison to multiple sclerosis which typi-
cally affects the cord in a patchy way and the lesions are 
usually peripheral. Perivascular spread of monocytes; lym-
phocytes infiltrating focal areas of the cord along with astro-
glial and microglial activation are invariable findings on 
histopathology of TM. In some biopsies during the acute 
phases of TM, infiltrates of CD4
+ and CD8
+ T-lymphocytes 
were found to be prominent suggesting immune-mediated 
disease process. There is typically preservation of the subpial 
parenchyma suggesting ischemia as the ultimate cause of   
the cord lesions in TM. The pathology also differs depending 
on the etiology. For example necrotizing myelitis can be 
seen in NMO (see below) and paraneoplastic myelitis [35]. 
In MS and acute disseminated encephalomyelitis (ADEM) 
the lesions tend to have predilection to the white matter in 
comparison to the circumferential involvement in idiopathic 
TM [36].  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). T2 Sagittal spine MRI of a 30 year old lady presented to 
our hospital with left lower extremity weakness and low back pain 
showing the typical fusiform cord signal in TM. 
  Various infections precede 30-60% of the cases of TM 
[1, 3, 4, 7-9, 11, 37]. Reported infections include, but not 
limited to: herpesviridae, enteroviruses, influenza viruses, 
adenoviruses; coxsackie viruses; enteric cytopathogenic hu-
man orphan (ECHO) virus, hepatitis A virus; lymphocytic 
choriomeningitis virus (LCMV); mumps virus; measles vi-
rus, rubella virus, poliovirus, rubeola virus, dengue virus, 
Russian spring-summer encephalitis virus, varicella virus, 
mycoplasma pneumonia bacteria, legionella pneumonia bac-
teria, pulmonary tuberculosis, borrelia (Lyme disease), liste-
ria, and bartonella (cat scratch disease) [4, 11, 38, 39]. About 
30% of pediatric cases are preceded with immunizations 
within one month of disease onset [7, 11]. 
  Infections can cause TM through direct tissue damage, 
[39-41] or by immune-mediated infection-triggered tissue 
damage which may be due to molecular mimicry or superan-
tigen effect. The molecular mimicry theory is based on the 
fact that several infectious agents are capable of encoding 
molecular structures (e.g. proteins, glycolipids or proteogly-
cans) that mimic self antigens [4, 42-44]. Immune response 
to the mimic “pseudo-self” then may result in cross-reactive 
immune activation against self tissue. The immune response 
can be either T-cell mediated or antibody mediated. Superan-
tigens are microbial peptides that are capable of inducing 
fulminant immune response by activating a large number   
of lymphocytes including autoreactive T- cells in a unique 
fashion by binding to the V region of T cell receptor instead 
of highly variable peptide groove [45-49]. Superantigens   
are also capable of activating T- lymphocytes in the total 
absence of co-stimulatory molecules. 
  A non-microbial related immune dysfunction has been 
also proposed in the immunopathogenesis of TM. Some 
studies have described the presence of autoantibodies in TM 
[18, 22, 50].Interleukin 6 (IL-6) levels were also markedly 
elevated in the spinal fluid of TM patients in comparison to 
control patients and to MS patients, and this also correlated 
with disability [4, 51]. IL-6 is secreted by astrocytes and 
microglia and binds to oligodendroglia and axons. High lev-
els of IL-6 can cause direct tissue injury and indirect damage 
by inducing nitric oxide synthetase in microglia. Interest-
ingly, Interferon-beta (IFN-), a medication used to treat 
MS, was found to induce IL-6 [52]. IL-6 has probably a bell-
shaped effect where at certain levels could cause damage and 
at different levels can induce repair [51, 53, 54].  
  One study that was conducted in Japan found that several 
patients with TM have much higher serum IgE levels than 
MS patients or controls pointing towards immune-mediated 
process as well [55]. Concordant with these findings, tissue 
biopsies of two patients with TM and elevated total and spe-
cific serum IgE disclosed the presence of antibody deposi-
tion within the spinal cord and perivascular infiltration with 
eosinophils that could induce tissue damage [56].  
Current Therapies  
  The main therapies available for TM include: high dose 
intravenous methylprednisolone (IVMP), plasma exchange 
and/or intravenous cyclophosphamide. There are no placebo-
controlled randomized trials to support the use of IVMP in 
TM despite the positive clinical experience. However, there 
are several small observational studies that documented 
clinical benefit of IVMP in TM, if given in the acute phase, 
in terms of faster recovery and disability in addition to good 
tolerability [57-62]. The rationale of using steroids in TM is 
based on its numerous effects on the immune system leading 
to a global immunosuppression. Some of these effects in-
clude but not limited to: inhibition of lymphocyte prolifera-
tion and differentiation, redistribution of lymphocytes,   
alteration of lymphokine function especially tumor necrosis 
factor (TNF), IL-1 and IL-2, and inhibition of macrophage 
function, in particular antigen presentation and processing.  
  In comparison to steroids, use of plasma exchange in TM 
is supported by randomized trials. It is commonly initiated in 
severe cases of TM and in cases unresponsive to pulse ster-
oids. Plasma exchange is an effective way to remove 
“autoreactive antibodies” and other toxic molecules from the 
plasma and hence, it is a very common procedure in the 
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studies have shown significant clinical benefit for plasma 
exchange in TM [63-66]. Based on the NMO literature (see 
below), early initiation of plasma exchange within 20 days of 
attack onset predicts greater likelihood of clinical response 
[65]. 
  There is currently no solid evidence to support the use of 
immunosuppressive therapy in TM. Cyclophosphamide, an 
alkylating agent that showed some promising results in MS 
can be used in idiopathic TM, especially in severe cases [67]. 
A retrospective study of 13 patients with idiopathic TM, in-
travenous cyclophosphamide in combination with plasma 
exchange was shown to be superior to plasma exchange 
alone in patients with complete TM [66]. Cyclophos-
phamide, in addition to its antimitotic effect, has significant 
immunosuppressive and immunomodulatory actions making 
it an effective treatment for immune-mediated disorders. It 
causes suppression of cell-mediated and humoral immunity 
through its actions on T cells and B cells [68]. In multiple 
sclerosis, for example, cyclophosphamide was shown to de-
crease the secretion of the pro-inflammatory cytokines like 
IFN- and IL-12 and increase the secretion of the anti-
inflammatory cytokines like IL-4 and IL-10 in cerebrospinal 
fluid (CSF) and peripheral blood [69]. However, due to the 
significant side effects like gonadotoxicity and bladder toxic-
ity its use should be individualized and carefully initiated 
and monitored. Other oral immunosuppressive agents like 
mycophenolate, azathioprine and methotrexate can also be 
considered in recurrent cases despite the lack of evidence. In 
our clinical experience we use IVMP alone if the patient 
presents with non-motor symptoms, plasma exchange in pa-
tients presenting with incomplete TM with motor symptoms 
and cyclophosphamide if the patient presents with complete 
TM. Cyclophosphamide, in our experience is a well-tolerated 
and a relatively safe medication if used appropriately and in 
the right clinical setting. We discussed cyclophosphamide in 
great details in a separate review that was recently published 
in 2009 [67]. 
 Interferon- (IFN-) and glatiramer acetate (GA) have   
a well-established role in MS and they are FDA-approved for 
the treatment of MS. They also have well-documented benefit 
in clinically isolated syndromes with brain lesions [70-73]. 
In conclusion, IFN- and GA would be ideal choices in pa-
tients with TM that carry a high risk of conversion to MS.  
  The ultimate therapy of TM would be targeted therapy 
once the targets are clearly defined. Like in all neurological 
disorders, the search for the ideal neuroprotection that can  
be used in combination with the treatments mentioned above 
probably provides the most practical treatment strategy   
at this time. The use of erythropoietin in TM is under inves-
tigation. Erythropoietin was shown to be neuroprotective   
in different models of nerve injury in animal studies, [74, 75] 
and clinical studies are planned to investigate the safety,   
tolerability and efficacy of erythropoietin in TM patients.  
NEUROMYELITIS OPTICA SPECTRUM (DEVIC’S 
DISEASE) 
  Neuromyelitis optica (NMO) is an idiopathic, probably 
immune-mediated, destructive demyelinating syndrome of 
the CNS with predilection to optic nerves and spinal cord.  
Epidemiology and Clinical Profiles  
  NMO has a significant female to male predominance 
(9:1), and affects mainly young people with a median age of 
onset in the late 30’s [76-78]. In the United States it mainly 
affects Caucasians but the other racial groups are signifi-
cantly afflicted in comparison to MS [76, 77, 79-81]. NMO 
does occur in children with an average age of 10 years (7-14 
years) [82, 83]. Opticospinal MS (OSMS), which is contro-
versially recognized as part of NMO spectrum, is prevalent 
in Japan [84]. NMO may account for 1% of inflammatory 
demyelinating disease (IDD) of the CNS among Caucasians, 
but represents almost 30% of total IDD in Japan [85]. 
  Familial clusters of NMO have been described in   
scattered reports in the literature with no conclusive evidence 
[86, 87]. 
  NMO is quite different from MS clinically, radiologi-
cally, pathologically and in terms of treatment approaches. 
The distinction is of paramount importance because man-
agement and prognosis are fundamentally different. Clinical 
onset is usually acute and in two thirds of cases, a prodrome 
of flu-like symptoms may precede neurologic deficits [82, 
88]. Various viral and non-viral infectious have been seen to 
precede neurologic symptoms of NMO with no conclusive 
association [89-96]. 
  The first manifestation of neuromyelitis optica is ON in 
up to three fourths of patients, TM in up to one third and 
concomitant ON and TM in up to one tenth of patients [88, 
97]. The interval between visual and cord symptoms is ex-
tremely variable, ranging between days to years [88, 98, 99]. 
ON is unilateral in 65-85%, but bilateral simultaneous ON or 
sequential ON in rapid succession is more suggestive of 
NMO [100]. NMO-ON clinical features are similar to MS-
related ON but more severe leading to complete visual loss 
in 40% of patients [101]. In 5 years, more than half of pa-
tients with relapsing NMO are blind in one or both eyes or 
require ambulatory help [100]. NMO-TM is usually severe, 
as well. It is typically longitudinally extensive TM (LETM); 
extending over 3 or more cord signals [101]. The spinal cord 
inflammation is usually symmetric causing symmetric in-
volvement of motor and sensory tracts [101]. Cervical 
LETM in NMO may extend into the medulla resulting in 
nausea, persistent hiccups, and even fulminant respiratory 
failure [88, 102]. Lhermitte sign, tonic spasms and radicular 
pain are reported in one third of NMO patients [101, 103]. 
Lhermitte sign and the paroxysmal tonic spasm indicate a 
relapsing more than a monophasic course [101]. 
  NMO is monophasic in 10-30% of cases and relapsing 
60-90% of cases [101]. As mentioned above, NMO ON and 
TM attacks are typically more severe and recovery is less 
complete compared with MS [100].The relapse rate is higher 
than in MS, frequency of a second episode within the first 2 
years is also higher than in MS ( 82% vs. 62%) and the me-
dian time to reach expanded disability status scale (EDSS) of 
6.0 is shorter than MS( 7.0 years vs. 9.4 years) [97]. Re-
lapses occur within 6 months of the initial attack in 55% of 
patients, within 18 months in 27%, and after 5 years in 18% 
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months [97]. In comparison to adults, children with NMO 
have fewer relapses [82, 104].  
  In contrast to MS, secondary progression is quite rare and 
progression only takes place during the attack and disability 
is a result of the clinical cumulative effect of relapses rather 
than secondary progression [100]. The monophasic form has 
a better prognosis than the relapsing form [97-99, 101]. The 
survival rate at 5 years may amount to 90% in the monopha-
sic groups and 68% in the relapsing group. Poor outcome 
and mortality are directly related to high relapse rate during 
the first 2 years [97, 100, 105]. 
  MR imaging of the spine is very helpful in diagnosing 
NMO. In the acute phase it typically shows LETM with a T2 
cord signal with cord expansion and gadolinium enhance-
ment (Fig. 2a) [106]. In the chronic stage the enhancement 
and expansion resolve while the T2 signal persists but the 
LETM regresses to less than 3 segments and breaks up into 
shorter fragments and the cord becomes atrophic (Fig. 2b) 
[106]. Up to 60% of NMO patients will develop non-specific 
asymptomatic subcortical white matter lesions at a mean 
follow up of 6+/-5 years [107]. Ten percent of patients have 
specific lesions in the diencephalon (thalamus, hypothala-
mus), corpus callosum, hypophysis, brainstem (periaqueduc-
tal) and around 10% of NMO patients will develop lesions 
that meet the specific MS criteria [107-109]. Magnetization 
transfer (MT) and diffusion tensor imaging (DTI) disclosed 
microscopic pathology in the normally appearing gray matter 
(NAGM) in the brain of patients with NMO [110].  
 
 
 
 
 
 
 
 
 
 
 
Fig. (2a, b). Fig. (2a) shows a T2 sagittal spine MRI of a 38 year-
old woman who presented to our hospital with acute incomplete 
paraparesis displaying the typical LETM in acute NMO. Fig. (2b) 
shows a T2 sagittal spine MRI of a 51 year-old woman with chronic 
relapsing NMO showing the typical manifestations of chronic 
NMO including cord atrophy and patchy lesions. 
  Optical coherence tomography (OCT) is a relatively new 
noninvasive method of evaluating the thickness of the retinal 
nerve fiber layer (RNFL). The mean retinal nerve fiber layer 
thickness is significantly reduced in patients with NMO 
compared with controls and has good correlation with EDSS 
[111]. Findings on OCT could potentially differentiate   
NMO ON vs. MS ON. NMO ON is associated with a thinner 
mean RNFL compared to MS and the superior and inferior 
quadrants were more severely affected in NMO than MS 
[112-114]. 
  In terms of CSF studies, NMO profile is quite distinct 
from MS. The white blood cell count (WBC) is usually 50-
1000 cells/mm3 vs. 0-50 in MS, shows neutrophilic pre-
dominance vs. lymphocytic predominance in MS [101]. CSF 
pleocytosis is more prominent during the acute attack of TM 
more than ON and has a specificity of 95% and sensitivity of 
less than 30% [101]. Patients with severe TM accompanied 
by marked CSF pleocytosis (more than 100 leukocytes/mm3) 
have typically poor outcome [88]. CSF oligoclonal bands are 
seen in 15-30% in NMO vs. 85% in MS and have low sensi-
tivity and specificity in NMO [101]. An elevated IgG index 
is only seen in 20% of NMO patients [101]. Up to one half 
of patients with NMO have positive serological immunologi-
cal markers like (antinuclear antibody (ANA), extractable 
nuclear antigens (ENAs), anti-thyroid antibodies, anti-
cardiolipin antibodies, anti-parietal cell antibodies and   
acetylcholine receptor antibodies [101, 115-120].  
  Seropositivity for Sjögren’s’ syndrome (SS)-A (anti-Ro) 
antibody is modestly predictive of relapse in patients with 
the first TM attack, seen in 77% of relapsing NMO vs. 33% 
of monophasic NMO [121]. For relapsing NMO, the odds 
ratio for having another autoimmune disease is increased by 
10-fold [100]. Risk factors for recurrence include: NMO-IgG 
seropositivity, female gender, older age (>30 years), less 
severe motor impairment after the myelitic onset, longer 
interval between the first and second attack (>6 months) and 
systemic autoimmunity [88, 100, 101].  
  Diagnostic Criteria for NMO were initially proposed   
in 1999 [101]. However, the discovery of NMO-IgG anti- 
body [122] revolutionized the diagnosis of NMO and the 
criteria were revised in 2006 (Table 3) [84]. In a cohort of 
patients examined between 1999 and 2005, the new criteria 
were 99% sensitive and 90% specific for neuromyelitis   
optica, compared to the previous criteria, which were   
85% sensitive and 48% specific [123]. In summary, NMO 
antibody and MRI spine are the most important diagnostic 
tools for NMO.  
Table 3.  Revised Diagnostic Criteria for Definitive NMO  
1.    Optic neuritis 
2.    Acute myelitis 
3.    Two out of three supportive criteria that include: 
•  Continuous spinal cord MRI lesion extending over 3 or more verte-
bral segments 
•  Brain MRI not meeting diagnostic criteria for MS 
•  NMO-seropositive status  
 
  The discovery of NMO antibody has revolutionized   
the accuracy of NMO diagnosis and broadened the spectrum 
of NMO syndromes more than previously appreciated but   
its role in pathogenesis is controversial and unclear. NMO 
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[122]. Its sensitivity ranges from 58-76% and specificity 
ranges from 85- 99% [84, 122, 124, 125]. In a large study 
comparing the sensitivity and specificity of immunofluores-
cence (IF) and immunoprecipitation (IP) assays using green 
fluorescent protein-tagged Aquaporin-4 (AQP4), the sensi-
tivity rates for NMO were higher using IF technique and 
improved by 5% using combined methods [126]. NMO anti-
body is also seen in syndromes closely related to NMO, for 
example: recurrent LETM (52%), recurrent isolated ON 
(25%), and the Japanese form of optic-spinal MS (58%) 
which expands NMO to syndromes rather than one disease 
though the associations are still debatable and not completely 
understood [122]. Its target antigen is the water channel   
aquaporin-4 (AQP-4). Aquaporins are involved in fluid   
balance and cell water homeostasis and AQP-4 is the most 
common type found in the CNS specifically on astrocytes 
foot processes, the abluminal surface of blood vessels   
(glia limitans) and concentrated in the periependymal regions 
of the brain [127-129]. We will discuss the role of NMO 
antibody in NMO pathogenesis in a separate section. In   
conclusion, NMO is a very specific marker that defines the 
NMO spectrum of disorders: complete NMO and incom-
pletely developed (restricted) type of NMO [77, 122, 130]. 
Its role in pathogenesis is unclear. It was shown also to   
predict a relapsing course and a poor outcome in some   
studies [123, 131].  
Pathology, Pathogenesis and Pathophysiology  
  Spinal cord specimens from patients with NMO typically 
show evidence of perivascular inflammatory demyelination 
with high proportion of polymorphonuclear cells (PMN) and 
eosinophils, deposition of IgM and complement C9 neoanti-
gen in addition to hyalinization of spinal cord arteries with 
gray and white matter necrosis [102, 129, 132-135]. Contrary 
to MS lesions, there is rare infiltration with CD3 
+ and CD8
+ 
lymphocytes [85]. Prominent vasculocentric IgG and com-
plement deposits, with vascular proliferation and fibrosis are 
also typical findings in NMO and correspond to AQP-4 site 
of expression and might be related to humoral immune acti-
vation and a pathogenic NMO-IgG. The anterior optic path-
way shows significant demyelination and cavitation in NMO 
specimens as well [98].  
  The etiology of neuromyelitis optica remains unknown. 
A possible role for autoimmunity in the pathogenesis is sug-
gested by several observations. The overlap with other auto-
immune diseases and the wide range of positive autoantibod-
ies in the serum of patients with NMO, as mentioned above, 
suggests polycloncal B cell activation [132]. The discovery 
of the specific NMO antibody supports the autoimmune   
theory as well. The role of infections in NMO pathogenesis 
is not clear, but the various infections that may precede 
NMO neurological symptoms could theoretically induce 
immune dysregulation (see the section on infections and 
TM). The immunohistological findings of prominent infiltra-
tion with neutrophils, eosinophils, and IgM deposition in   
the lesions also support the immunological theory, especially 
the significant involvement of humoral immunity in the   
immunopathogenesis of NMO. A recent molecular study by 
Pentón-Rol and co-workers found that the levels of IL-10 
and tumor necrosis alpha (TNF-) were undetectable point-
ing to immunoregulatory dysfunction [136]. The good clini-
cal response to immunomodulatory treatments (see below) 
also supports the immune theory. Besides, increased number 
of myelin oligodendrocyte glycoprotein-specific B cells was 
also demonstrated in NMO pointing towards dysregulation 
of humoral immunity [137]. Very interestingly, several re-
ports have described elevated prolactin levels in some pa-
tients with NMO spectrum [108, 138, 139]. The elevated 
prolactin levels were seen mostly in Asian and black women 
and was concordant with the presence of ON. The elevated 
prolactin could be a result or a contributing factor. The ex-
tension of inflammation to involve the hypothalamus could 
result in disinhibition of prolactin release. Prolactin, on the 
other hand, is a potent immune stimulant for T helper cell 1 
(TH1) cell responses that could be involved in the initiation 
or sustenance of the neuroinflammation [140]. Of note,   
elevated prolactin levels is not a unique finding to NMO and 
there are numerous reports of hyperprolactinemia in other 
autoimmune diseases especially SLE [141, 142]. 
  The role of genetic factors in NMO is not determined   
yet. There is evidence, however, that NMO is associated with 
HLA alleles DR1*801, DP1 501, DPA1 202, DPB1*1501, 
DRB*03 but not with DRB1*1501 or DRB5*0101, which   
are classically associated with MS [143-146]. These findings 
may suggest a possible genetic role in the disease process. 
  The role of NMO Ig-G antibody in the immunopatho-
genesis of NMO is quite complicated and not well-
understood. The observation that brain lesions in NMO occur 
in areas with high concentration of AQP-4 brought the atten-
tion to the role of the anti-AQP-4 antibody in the disease 
process [107]. However, there are several observations that 
argue against the pathogenic role of the antibody. Firstly, 
The brain lesions are not really the sine qua none of NMO 
and they’re usually clinically insignificant despite the high 
density of AQP-4 in the brain. In addition, AQP-4 is present 
in the kidney and gastrointestinal tract, but involvement of 
these regions has not been described in neuromyelitis optica 
so far and AQP-4 does not explain the distribution of NMO 
lesions. Pathological studies have failed to demonstrate the 
presence of NMO antibody in NMO lesions [147, 148]. 
  The NMO experience with animal models is very   
interesting. When human NMO-IgG antibody was given to 
rats, NMO pathology could not be reproduced, but when it 
was injected into animals induced for experimental auto- 
immune encephalomyelitis (EAE), NMO lesions were then 
reproduced. The conclusion that can be drawn from these 
findings is that a disruption of blood brain barrier may facili-
tate the pathogenic role (if any) of NMO antibody. The bot-
tom line is that the pathogenic role of the AQP-4 antibody is 
unknown and needs to be studied more carefully before 
drawing any solid conclusion.  
  The relation between NMO and OSMS is controversial 
and debatable. For example, several reports argued that 
OSMS is quite distant from NMO from a pathologic point of 
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OSMS is mostly T helper cell 1 (TH1)-related disease in 
comparison to NMO which is thought to be T helper cell 2 
(TH2) and B-lymphocyte-driven making them completely 
different diseases. Further studies are needed to clarify the 
relation between NMO and OSMS.  
Curent Therapies (Table 4) 
  There are currently no FDA-approved medications for 
NMO due to the lack of large double-blinded randomized 
placebo-controlled trials.  
  Intravenous pulse steroids (IVMP 1 gram IV every 24 
hours for 5 days followed by oral steroid taper is the usual 
treatment of acute attacks of NMO [151]. The immunologi-
cal effects of steroids are discussed in the TM section. Res-
cue treatment with plasma exchange is supported by several 
clinical trials [63, 65, 152]. Early initiation of plasma ex-
change within 20 days of attack onset predicts greater likeli-
hood of clinical response [65]. There are few case reports of 
lymphocytapheresis as being effective in NMO as well 
[153]. Plasma exchange and lymphocytapheresis aim at re-
moving the “pathogenic” factors from plasma as mentioned 
above in the TM section.  
  The most promising treatment for relapsing NMO is 
probably rituximab. Rituximab is a monoclonal antibody that 
targets cluster of differentiation (CD) 20+ cells but its exact 
mode of action remains unclear [154]. Possible actions may 
include: induction of antibody-dependent cell cytotoxicity 
(ADCC) and complement-dependent cytotoxicity, regulatory 
effects on cell cycle, increase antigen presentation, down-
regulation of B-cell receptors and induction of B-cell apop-
tosis. An open label study of the effects of rituximab in 
NMO showed that 6/8 patients with worsening NMO refrac-
tory to prior therapy, treated with IV rituximab, remained 
relapse free for a 6-18- month-follow up and the median at-
tack rate declined from 2.6 to 0 attacks per patient per year 
(p=0.0078) [155]. The typical dose used is 1000mg (1gm) or 
375mg/m2 IV infusion followed by monthly monitoring of 
CD19 count and once CD19 levels are detectable, rituximab 
is redosed [155]. Side effects of rituximab may include but 
not limited to: infusion-related reactions, increased risk for 
reactivation of tuberculosis (TB), hepatitis B virus (HBV) 
and JC virus [155]. Jacob and co-workers conducted a retro-
spective analysis of 25 patients with NMO of whom 23 had 
frequent relapses despite the use of medical therapy [156]. 
Infusions of rituximab at median intervals of 8 months de-
creased the median relapse rate after a median follow up of 
19 months (0-3.2 (post-treatment) vs. 0.5-5 (pre-treatment) 
relapses, P <.001). Very recently, a trial of rituximab in 3 
patients with NMO showed significant reduction of relapse 
rate [157]. The annualized relapse rate for the 3 patients dur-
ing the year before rituximab therapy was 4, 5, and 6, respec-
tively, and this decreased to 3, 1, and 0 in the year after ther-
apy. In our clinical experience, we use one induction dose of 
rituximab and then we follow the CD19 counts and redose 
once the CD19 is detectable (1%), typically every 6-9 
months for  2 years. Weekly infusions of rituximab for 4 
weeks as induction protocol have been used especially in 
treating rheumatologic disorders like refractory rheumatoid 
arthritis [158]. The natural course of the disease in NMO 
mandates  aggressive and emergent treatment because the 
attacks carry a high risk of disability and in some cases the 
attacks can be fatal. It cannot be overemphasized that NMO 
should be treated aggressively since we have a very small 
room for trial and error. Studies comparing the efficacy and 
safety of different dosing regimens are needed to unify our 
approach in treating these patients.  
  In our experience, if a patient relapses while sufficiently 
treated with rituximab, we treat the acute exacerbation with 
high dose IV steroids in addition to plasma exchange and IV 
Table 4.  Management of Neuromyelitis Optica 
Medication   Use   Typical dose   Evidence  
High dose IV  
methylprednisolone 
Acute   1 gm IV daily for 5 days with or without a taper   Observational studies  
Plasma exchange   Acute as a rescue therapy  5 exchanges (each exchange 250 ml) over 5-10 days   Randomized trials in TM patients 
Rituximab   Maintenance   1 gm (or 375 mg/m
2) IV every 1-2 weeks for 2-4 weeks  
then redoes based on CD19 count (typically  
every 6-8 month) for  2 years  
Several open label and  
retrospective clinical trials  
Azathioprine   Maintenance   2 mg/kg PO divided BID (typically 100 mg BID) for 2 years   Observational studies  
Mycophenolate  Maintenance  1-3 gm PO daily divided BID or TID for 2 years   Retrospective trial  
Methotrexate   Maintenance  5-15 mg PO weekly for 2 years  Open label trial  
Mitoxantrone   Maintenance  12 mg/m
2 every 3 months (maximum dose 140 mg/m
2)  Open label trial 
Cyclophosphamide Maintenance  0.5-1.5  mg/m
2 (typically 1 gm) IV every month until  
absolute lymphocyte count<1000/mm
3 (typically 6 cycles) or 
immunoablative dose of 200 mg/kg divided over 4 days 
Open label trial 
IVIG   Maintenance  2 gm/kg induction followed by 0.4-0.5 gm/kg every month  Case series  424    Current Neuropharmacology, 2011, Vol. 9, No. 3  Awad and Stüve 
cyclophosphamide in refractory cases. After stabilizing the 
patient we would switch the patient to IV cyclophosphamide. 
  Other immunomodulatory therapies that have showed 
good results in NMO include: azathioprine, mitoxantrone, 
methotrexate, mycophenolate, cyclophosphamide and intra-
venous immunoglobulin (IVIG). Azathioprine (2-3 mg/kg/ 
day) in combination with oral prednisone (1mg/kg/day) was 
used in an observational case series of 7 patients was shown 
to be effective in prevention of relapses in NMO [159]. The 
drug is a purine analog which is metabolized to 6-
meraptopurine (MP) and ultimately, becomes incorporated 
into replicating DNA and can also block the de novo path-
way of purine synthesis [160]. Its relative specificity to lym-
phocytes is explained by the lack of the salvage pathway of 
purine synthesis [160]. Mitoxantrone was also shown to be 
helpful in NMO [161]. Mitoxantrone is as a doxorubicin 
analogue that modulates the immune system by several 
mechanisms. It suppresses the proliferation of T cells, B 
cells, and macrophages, impairs antigen presentation and 
decreases the secretion of proinflammatory cytokines, en-
hances T-cell suppressor function and inhibits B-cell func-
tion and antibody production and inhibits macrophage-
mediated myelin degradation [162]. Methotrexate was also 
tried in NMO and showed some benefit. Methotrexate, at 
lower doses, has been shown to be very effective for the 
management of many autoimmune disease due the inhibition 
of enzymes involved in purine metabolism, leading to accu-
mulation of adenosine, or the inhibition of T cell activation 
and suppression of intercellular adhesion molecule expres-
sion by T cells [163]. Mycophenolate is another immuno-
suppressant that has been used in NMO patients. It was 
found to decrease relapse rate in a retrospective trial of 24 
patients with NMO spectrum [164]. Mycophenolate mofetil 
is metabolized in the liver to the active moiety mycophenolic 
acid which then inhibits inosine monophosphate dehydro-
genase, the enzyme that controls the rate of synthesis of gua-
nine monophosphate in the de novo pathway of purine syn-
thesis used in the proliferation of B and T lymphocytes 
[165]. As mentioned above, the lack of salvage pathway in 
lymphocytes renders them targets for the action of inhibitors 
of de novo pathway of purine synthesis. Immunoablative 
doses of cyclophosphamide were shown to control disease 
progression in intractable cases of NMO [166]. Immunologi-
cal mechanisms of action of cyclophosphamide are described 
in the TM section. Using immunoablative doses of cyclo-
phosphamide is an intriguing and relatively novel approach 
that had very promising results in MS as well [67]. Repeated 
IVIG infusions were also used in 2 patients with NMO and 
showed some positive results [167]. The exact mechanism by 
which IVIG suppresses inflammation has not been defini-
tively established but is believed to involve the inhibitory Fc 
receptor which can lead to decreased antigen presentation 
[168].  IVIG may work via inducing an immune complex 
formation that binds Fc receptors on dendritic cells that 
probably mediate its anti-inflammatory effects [169]. It may 
also work by directly binding the pathogenic antibodies or 
via complement activation “complement scavenging effect” 
[170]. IVIG also reacts with a number of membrane recep-
tors on T cells, B cells, and monocytes that are pertinent to 
autoreactivity and induction of tolerance to self [171]. A 
recent report stated that IVIG application to activated T cells 
leads to their decreased ability to engage microglia [172].  
  Immunomodulators that are typically used in treating MS 
like IFN- were found to be ineffective and even harmful in 
patients with NMO based on small trials [173]. Up to our 
knowledge, there is only one reported case of NMO that re-
sponded to GA [174]. Making decisions on single reported 
cases can be done but with extreme caution. Based on the 
current evidence, we cannot recommend using IFN- and 
GA in the treatment of NMO. Since recovery is usually in-
complete and the attack is more debilitating than in MS, 
there is a small room for trial and error when it comes to 
treatment of NMO and only the most effective treatment 
should be offered.  
  As we mentioned in the TM section, future therapeutic 
approaches should focus on neuroprotection and targeted 
therapy. There no ongoing clinical trials, up to our knowl-
edge, studying neuroprotection in NMO. 
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